Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Regeneron Pharmaceuticals...

    NASDAQ: REGN · Real-Time Price · USD
    493.12
    10.05 (2.08%)
    At close: Jun 06, 2025, 3:59 PM
    494.76
    0.33%
    After-hours: Jun 06, 2025, 05:59 PM EDT

    Regeneron Pharmaceuticals Statistics

    Share Statistics

    Regeneron Pharmaceuticals has 106.15M shares outstanding. The number of shares has increased by -0.79% in one year.

    Shares Outstanding

    n/a
    		 106.15M

    Shares Change (YoY)

    n/a
    		 -0.79%

    Shares Change (QoQ)

    n/a
    		 -0.52%

    Owned by Institutions (%)

    n/a
    		 86.48%

    Shares Floating

    n/a
    		 n/a

    Failed to Deliver (FTD) Shares

    n/a
    		 73

    FTD / Avg. Volume

    n/a
    		 0.01%

    Short Selling Information

    The latest short interest is 2.8M, so 2.59% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 2.8M

    Short % of Shares Out

    n/a
    		 2.59%

    Short % of Float

    n/a
    		 2.73%

    Short Ratio (days to cover)

    n/a
    		 1.85

    Valuation Ratios

    The PE ratio is 17.42 and the forward PE ratio is 12.26. Regeneron Pharmaceuticals's PEG ratio is 1.68.

    PE Ratio

    n/a
    		 17.42

    Forward PE

    n/a
    		 12.26

    PS Ratio

    n/a
    		 5.41

    Forward PS

    n/a
    		 2.9

    PB Ratio

    n/a
    		 2.62

    P/FCF Ratio

    n/a
    		 20.97

    PEG Ratio

    n/a
    		 1.68
    Financial Ratio History

    Enterprise Valuation

    Regeneron Pharmaceuticals has an Enterprise Value (EV) of 77.08B.

    EV / Sales

    n/a
    		 5.43

    EV / EBITDA

    n/a
    		 14.49

    EV / EBIT

    n/a
    		 17.44

    EV / FCF

    n/a
    		 21.03

    Financial Position

    The company has a current ratio of 4.73, with a Debt / Equity ratio of 0.09.

    Current Ratio

    n/a
    		 4.73

    Quick Ratio

    n/a
    		 3.95

    Debt / Equity

    n/a
    		 0.09

    Debt / EBITDA

    n/a
    		 0.51

    Debt / FCF

    n/a
    		 0.74

    Interest Coverage

    n/a
    		 72.3

    Financial Efficiency

    Return on Equity is 15.03% and Return on Invested Capital is 10.89%.

    Return on Equity

    n/a
    		 15.03%

    Return on Assets

    n/a
    		 11.69%

    Return on Invested Capital

    n/a
    		 10.89%

    Revenue Per Employee

    n/a
    		 $936,930.99

    Profits Per Employee

    n/a
    		 $291,107.01

    Employee Count

    n/a
    		 15,158

    Asset Turnover

    n/a
    		 0.38

    Inventory Turnover

    n/a
    		 0.64

    Taxes

    Income Tax

    n/a
    		 367.3M

    Effective Tax Rate

    n/a
    		 7.68%

    Stock Price Statistics

    The stock price has increased by -50.83% in the last 52 weeks. The beta is 0.31, so Regeneron Pharmaceuticals's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.31

    52-Week Price Change

    n/a
    		 -50.83%

    50-Day Moving Average

    n/a
    		 574.49

    200-Day Moving Average

    n/a
    		 774.66

    Relative Strength Index (RSI)

    n/a
    		 34.64

    Average Volume (20 Days)

    n/a
    		 1,314,125

    Income Statement

    In the last 12 months, Regeneron Pharmaceuticals had revenue of 14.2B and earned 4.41B in profits. Earnings per share was 40.9.

    Revenue

    n/a
    		 14.2B

    Gross Profit

    n/a
    		 12.23B

    Operating Income

    n/a
    		 3.99B

    Net Income

    n/a
    		 4.41B

    EBITDA

    n/a
    		 5.32B

    EBIT

    n/a
    		 4.84B

    Earnings Per Share (EPS)

    n/a
    		 40.9
    Full Income Statement

    Balance Sheet

    The company has 2.49B in cash and 2.7B in debt, giving a net cash position of -216.2M.

    Cash & Cash Equivalents

    n/a
    		 2.49B

    Total Debt

    n/a
    		 2.7B

    Net Cash

    n/a
    		 -216.2M

    Retained Earnings

    n/a
    		 31.67B

    Total Assets

    n/a
    		 37.55B

    Working Capital

    n/a
    		 14.01B
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was 4.42B and capital expenditures -755.9M, giving a free cash flow of 3.66B.

    Operating Cash Flow

    n/a
    		 4.42B

    Capital Expenditures

    n/a
    		 -755.9M

    Free Cash Flow

    n/a
    		 3.66B

    FCF Per Share

    n/a
    		 33.96
    Full Cash Flow Statement

    Margins

    Gross margin is 86.13%, with operating and profit margins of 28.1% and 31.07%.

    Gross Margin

    n/a
    		 86.13%

    Operating Margin

    n/a
    		 28.1%

    Pretax Margin

    n/a
    		 33.66%

    Profit Margin

    n/a
    		 31.07%

    EBITDA Margin

    n/a
    		 37.45%

    EBIT Margin

    n/a
    		 28.1%

    FCF Margin

    n/a
    		 25.8%

    Dividends & Yields

    REGN does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 5.74%

    FCF Yield

    n/a
    		 4.77%
    Dividend Details

    Analyst Forecast

    The average price target for REGN is $850, which is 72.4% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $850

    Price Target Difference

    n/a
    		 72.4%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 23
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 $204.5

    Lynch Upside

    n/a
    		 -58.53%

    Graham Number

    n/a
    		 500.32

    Graham Upside

    n/a
    		 1.46%

    Scores

    Altman Z-Score

    n/a
    		 7.15

    Piotroski F-Score

    n/a
    		 5

    Add to Watchlist